Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009.

Trotter CL, Findlow H, Borrow R.

Clin Vaccine Immunol. 2012 Feb;19(2):219-22. doi: 10.1128/CVI.05515-11. Epub 2011 Dec 21.

2.

Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.

Ceyhan M, Yildirim I, Balmer P, Riley C, Laher G, Andrews N, Borrow R, Kurt N, Turgut M, Aydogan A, Ecevit C, Uysal G, Schultze V.

Vaccine. 2007 Oct 10;25(41):7233-7. Epub 2007 Aug 1.

PMID:
17707957
3.

A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.

McVernon J, Nolan T, Richmond P, Reynolds G, Nissen M, Lambert SB, Marshall H, Papa T, Rehm C.

Pediatr Infect Dis J. 2012 Jan;31(1):e15-23. doi: 10.1097/INF.0b013e31823e1e34.

PMID:
22094636
4.

Meningococcal serogroup A, C, W, and Y serum bactericidal antibody profiles in Hajj pilgrims.

Memish ZA, Yezli S, Almasri M, Assiri A, Turkestani A, Findlow H, Bai X, Borrow R.

Int J Infect Dis. 2014 Nov;28:171-5. doi: 10.1016/j.ijid.2014.09.005. Epub 2014 Oct 12.

5.

Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.

Trotter C, Findlow J, Balmer P, Holland A, Barchha R, Hamer N, Andrews N, Miller E, Borrow R.

Clin Vaccine Immunol. 2007 Jul;14(7):863-8. Epub 2007 May 9.

6.

Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers.

Findlow H, Sow S, Borrow R, Tapia M, Haidara FC, Akinsola AK, Idoko OT, Diallo F, Adegbola R, Tang Y, Parulekar V, Chadha H, Mabey L, Holme D, Townsend K, Chaumont J, Laforce FM, Kulkarni PS, Marchetti E, Viviani S, Hassan-King M, Preziosi MP.

Clin Vaccine Immunol. 2011 Sep;18(9):1492-6. doi: 10.1128/CVI.05020-11. Epub 2011 Jul 13.

7.

Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source.

Gill CJ, Ram S, Welsch JA, Detora L, Anemona A.

Vaccine. 2011 Dec 9;30(1):29-34. doi: 10.1016/j.vaccine.2011.10.068. Epub 2011 Nov 7.

8.

Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction.

Ishola DA Jr, Borrow R, Findlow H, Findlow J, Trotter C, Ramsay ME.

Clin Vaccine Immunol. 2012 Aug;19(8):1126-30. doi: 10.1128/CVI.05655-11. Epub 2012 May 30.

9.

Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.

Trotter CL, Borrow R, Findlow J, Holland A, Frankland S, Andrews NJ, Miller E.

Clin Vaccine Immunol. 2008 Nov;15(11):1694-8. doi: 10.1128/CVI.00279-08. Epub 2008 Sep 30.

10.
11.

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.

Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, Findlow J, Borrow R, Pizza M, Giuliani MM, Medini D.

Vaccine. 2013 Oct 9;31(43):4968-74. doi: 10.1016/j.vaccine.2013.08.006. Epub 2013 Aug 14.

12.

An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine.

Chandramohan D, Hodgson A, Coleman P, Baiden R, Asante K, Awine E, Owusu-Agyei S, Boutriau D, Nelson CB, Greenwood B.

Vaccine. 2007 Sep 3;25 Suppl 1:A83-91. Epub 2007 May 7.

PMID:
17521782
13.

Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.

Siberry GK, Warshaw MG, Williams PL, Spector SA, Decker MD, Jean-Philippe P, Yogev R, Heckman BE, Manzella A, Roa J, Nachman S, Lujan-Zilbermann J; IMPAACT P1065 Protocol Team.

Pediatr Infect Dis J. 2012 Jan;31(1):47-52. doi: 10.1097/INF.0b013e318236c67b.

14.

Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.

Souza AR, Maruyama CM, Sáfadi MA, Lopes MH, Azevedo RS, Findlow H, Bai X, Borrow R, Weckx LY.

Vaccine. 2016 Aug 5;34(36):4327-34. doi: 10.1016/j.vaccine.2016.06.072. Epub 2016 Jul 6.

PMID:
27395566
15.

Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.

Siberry GK, Williams PL, Lujan-Zilbermann J, Warshaw MG, Spector SA, Decker MD, Heckman BE, Demske EF, Read JS, Jean-Philippe P, Kabat W, Nachman S; IMPAACT P1065 Protocol Team.

Pediatr Infect Dis J. 2010 May;29(5):391-6. doi: 10.1097/INF.0b013e3181c38f3b.

16.

Prospective survey on carriage of Neisseria meningitidis and protective immunity to meningococci in schoolchildren in Niamey (Niger): focus on serogroup W135.

Amadou Hamidou A, Djibo S, Elhaj Mahamane A, Moussa A, Findlow H, Sidikou F, Cisse R, Garba A, Borrow R, Chanteau S, Boisier P.

Microbes Infect. 2006 Jul;8(8):2098-104. Epub 2006 May 30.

PMID:
16777457
17.

Seroprevalence of Antibody-Mediated, Complement-Dependent Opsonophagocytic Activity against Neisseria meningitidis Serogroup B in England.

Humphries HE, Brookes C, Allen L, Kuisma E, Gorringe A, Taylor S.

Clin Vaccine Immunol. 2015 May;22(5):503-9. doi: 10.1128/CVI.00100-15. Epub 2015 Mar 4.

18.

Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis Serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom.

Blanchard-Rohner G, Snape MD, Kelly DF, O'Connor D, John T, Kibwana E, Parks H, Ford K, Dull PM, Pollard AJ.

Pediatr Infect Dis J. 2013 Jul;32(7):768-76. doi: 10.1097/INF.0b013e318292f425.

PMID:
23538521
19.

Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era.

Trotter C, Borrow R, Andrews N, Miller E.

Vaccine. 2003 Mar 7;21(11-12):1094-8.

PMID:
12559785
20.

Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine.

Fijen CA, Kuijper EJ, Drogari-Apiranthitou M, Van Leeuwen Y, Daha MR, Dankert J.

Clin Exp Immunol. 1998 Dec;114(3):362-9.

Supplemental Content

Support Center